DEBRA PALAZZI to Palivizumab
This is a "connection" page, showing publications DEBRA PALAZZI has written about Palivizumab.
Connection Strength
0.042
-
The value of budget impact analyses in evaluating targeted therapies-The case of RSV prophylaxis for preterm infants. Value Health. 2011 Jan; 14(1):201-2.
Score: 0.022
-
Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States. Value Health. 2010 Jan-Feb; 13(1):77-86.
Score: 0.020